Triglyceride–Glucose Index And Glycaemic Control In Adults With Type 2 Diabetes Mellitus In North-Central Nigeria: A Cross-Sectional Study
Keywords:
Fasting plasma glucose, Glycaemic control, HbA1c; Nigeria, Triglyceride–glucose index, Type 2 diabetes mellitusAbstract
Optimal glycaemic control is central to the management of type 2 diabetes mellitus (T2DM), but access to glycated haemoglobin (HbA1c) testing remains limited in some resource-constrained settings. The triglyceride–glucose (TyG) index, calculated from fasting plasma glucose and triglyceride concentrations, may provide an inexpensive adjunctive measure of glycaemic status. This hospital-based cross-sectional study assessed the relationship between TyG and conventional glycaemic biomarkers among 132 adults with T2DM attending Benue State University Teaching Hospital, Makurdi, Nigeria. Fasting plasma glucose, fasting triglycerides and HbA1c were measured using standard laboratory methods, and TyG was calculated as ln[triglyceride (mg/dL) × glucose (mg/dL)/2]. Correlations were assessed using Pearson and Spearman coefficients. Receiver operating characteristic analysis evaluated TyG for identifying poor glycaemic control (HbA1c ≥7.0%), and DeLong's test compared TyG and fasting plasma glucose. Poor glycaemic control was present in 103 (78.0%) participants. Mean TyG was higher in participants with poor than good glycaemic control (9.24 ± 0.57 vs 8.27 ± 0.35; p<0.001). TyG correlated positively with HbA1c (Pearson r=0.567; p<0.001) and fasting plasma glucose (r=0.779; p<0.001). TyG showed good discrimination for poor glycaemic control (AUC 0.932, 95% CI 0.884–0.971), with an optimal cut-off of 8.82 (sensitivity 78.6%, specificity 93.1%). Its AUC was significantly higher than that of fasting plasma glucose (0.872; p=0.044). TyG may therefore serve as a practical adjunctive biomarker of glycaemic control in resource-constrained settings, pending external validation of the population-specific cut-off.
References
1. Magliano DJ, Boyko EJ; Diabetes Atlas 11th edition scientific committee. Diabetes Atlas [Internet]. 11th ed. Brussels: International Diabetes Federation; 2025 [cited 2026 Aug 12]. Available from: https://diabetesatlas.org/.
2. Boyko EJ, Ong KL, Duncan BB. Worldwide trends in diabetes prevalence: the NCD-RisC study. Lancet. 2025;406(10499):131-132. doi:10.1016/S0140-6736(25)01079-7.
3. Adeloye D, Ige JO, Aderemi AV, Adeleye N, Amoo EO, Auta A, et al. Estimating the prevalence, hospitalisation and mortality from type 2 diabetes mellitus in Nigeria: a systematic review and meta-analysis. BMJ Open. 2017;7(5):e015424. doi:10.1136/bmjopen-2016-015424.
4. Adeleye JO. The hazardous terrain of diabetes mellitus in Nigeria: the time for action is now. Res J Health Sci. 2021;9(1):69-76. doi:10.4314/rejhs.v9i1.8.
5. Global Burden of Disease Collaborative Network. Global Burden of Disease Study 2021 (GBD 2021) [Internet]. Seattle (WA): Institute for Health Metrics and Evaluation (IHME); 2024 [cited 2026 Aug 12]. Available from: https://ghdx.healthdata.org/gbd-results-tool.
6. Chinenye S, Young E. State of diabetes care in Nigeria: a review. Niger Health J. 2011;11(4):101-106. doi:10.60787/tnhj.v11i4.67.
7. Chukwuani U, Godwin YD, Kester AD, Ngozi JC. Determinants of glycemic control among persons with type 2 diabetes mellitus in Niger Delta. Sahel Med J. 2016;19(4):190-195. doi:10.4103/1118-8561.196361.
8. Lubaki JPF, Omole OB, Francis JM. Glycaemic control among type 2 diabetes patients in sub-Saharan Africa from 2012 to 2022: a systematic review and meta-analysis. Diabetol Metab Syndr. 2022;14:134. doi:10.1186/s13098-022-00902-0.
9. Camara A, Baldé NM, Sobngwi-Tambekou J, Kengne AP, Diallo MM, Tchatchoua APK, et al. Poor glycemic control in type 2 diabetes in the South of the Sahara: the issue of limited access to an HbA1c test. Diabetes Res Clin Pract. 2015;108(1):187-192. doi:10.1016/j.diabres.2014.08.025.
10. Abonyi MC, Basil B, Ezeude CM, Ugwueze CV, Okwara CC, Abonyi PO, et al. Sociodemographic predictors of glycaemic control among adults with type 2 diabetes mellitus in a Nigerian population: implications for public health and service delivery. BMC Public Health. 2026;26:1352. doi:10.1186/s12889-026-27040-w.
11. Egwim JI, Igbonagwam H, Egwim AV, Danawi H, Ogugua I. Determinants of glycemic control in adult diabetic patients attending a Nigerian tertiary hospital. J Soc Behav Health Sci. 2025;19:1-15. doi:10.5590/JSBHS.2025.19.1686.
12. Meka IA, Okwor CJ, Arum EJ, Otokunefor O, Anyim OB, Ogamba MI. Short and long term glycemic control among type 2 DM patients in a resource-limited setting. Afr Health Sci. 2025;25(2):176-185. doi:10.4314/ahs.v25i2.23.
13. American Diabetes Association Professional Practice Committee. Standards of care in diabetes—2025. Diabetes Care. 2025;48(Suppl 1):S1-S352.
14. George JA, Erasmus RT. Haemoglobin A1c or glycated albumin for diagnosis and monitoring diabetes: an African perspective. Indian J Clin Biochem. 2018;33(3):255-261. doi:10.1007/s12291-018-0755-9.
15. Balungi PA, Niwaha AJ, Nice R, Rodgers L, Mubiru N, Mukasa R, et al. Impact of haemoglobin variants on the diagnostic sensitivity of glycated haemoglobin (HbA1c) assay methodologies in sub-Saharan Africa: a laboratory-based method validation study. Pan Afr Med J. 2024;48:10. doi:10.11604/pamj.2024.48.10.41679.
16. Gómez-Peralta F, Choudhary P, Cosson E, Irace C, Rami-Merhar B, Seibold A. Understanding the clinical implications of differences between glucose management indicator and glycated haemoglobin. Diabetes Obes Metab. 2022;24(4):599-608. doi:10.1111/dom.14638.
17. Chivese T, Hirst J, Matizanadzo JT, Custodio M, Farmer A, Norris S, et al. The diagnostic accuracy of HbA1c, compared to the oral glucose tolerance test, for screening for type 2 diabetes mellitus in Africa: a systematic review and meta-analysis. Diabet Med. 2022;39(4):e14754. doi:10.1111/dme.14754.
18. Simental-Mendía LE, Rodríguez-Morán M, Guerrero-Romero F. The product of fasting glucose and triglycerides as surrogate for identifying insulin resistance in apparently healthy subjects. Metab Syndr Relat Disord. 2008;6(4):299-304. doi:10.1089/met.2008.0034.
19. Alizargar J, Hsieh NC, Wu SV. The correct formula to calculate triglyceride-glucose index (TyG). J Pediatr Endocrinol Metab. 2020;33(7):945-946. doi:10.1515/jpem-2019-0579.
20. Simental-Mendía LE, Guerrero-Romero F. The correct formula for the triglycerides and glucose index. Eur J Pediatr. 2020;179(7):1171. doi:10.1007/s00431-020-03644-1.
21. Gounden V, Devaraj S, Jialal I. The role of the triglyceride-glucose index as a biomarker of cardio-metabolic syndromes. Lipids Health Dis. 2024;23(1):416. doi:10.1186/s12944-024-02412-6.
22. Avagimyan A, Pogosova N, Fogacci F, Aghajanova E, Djndoyan Z, Patoulias D, et al. Triglyceride-glucose index (TyG) as a novel biomarker in the era of cardiometabolic medicine. Int J Cardiol. 2025;418:132663. doi:10.1016/j.ijcard.2024.132663.
23. Tao LC, Xu JN, Wang TT, Hua F, Li JJ. Triglyceride-glucose index as a marker in cardiovascular diseases: landscape and limitations. Cardiovasc Diabetol. 2022;21(1):68. doi:10.1186/s12933-022-01511-x.
24. Lopez-Jaramillo P, Gomez-Arbelaez D, Martinez-Bello D, Abat MEM, Alhabib KF, Avezum A, et al. Association of the triglyceride glucose index as a measure of insulin resistance with mortality and cardiovascular disease in populations from five continents (PURE study): a prospective cohort study. Lancet Healthy Longev. 2023;4(1):e23-e33. doi:10.1016/S2666-7568(22)00247-1.
25. Selvi NMK, Nandhini S, Sakthivadivel V, Lokesh S, Srinivasan AR, Sumathi S. Association of triglyceride-glucose index (TyG index) with HbA1c and insulin resistance in type 2 diabetes mellitus. Maedica (Bucur). 2021;16(3):375-381. doi:10.26574/maedica.2021.16.3.375.
26. Moinester M, Gottfried R. Sample size estimation for correlations with pre-specified confidence interval. Quant Methods Psychol. 2014;10(2):124-130. doi:10.20982/tqmp.10.2.p124
27. World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191-2194. doi:10.1001/jama.2013.281053.
28. Timalsina S, Mahato S, Nepal S. Utility of triglyceride-glucose index in predicting glycemic control in type 2 diabetes mellitus. Birat J Health Sci. 2021;6(2):1444-1448. doi:10.3126/bjhs.v6i2.40308.
29. Babic N, Valjevac A, Zaciragic A, Avdagic N, Zukic S, Hasic S. The triglyceride/HDL ratio and triglyceride glucose index as predictors of glycemic control in patients with diabetes mellitus type 2. Med Arch. 2019;73(3):163-168. doi:10.5455/medarh.2019.73.163-168.
30. Kassab HS, Osman NA, Elrahmany SM. Assessment of triglyceride-glucose index and ratio in patients with type 2 diabetes and their relation to microvascular complications. Endocr Res. 2023;48(4):94-100. doi:10.1080/07435800.2023.2245909.
31. Anivatthira P. The correlation of triglyceride glucose index (TyG index) and hemoglobin A1C (HbA1C) in patients with type 2 diabetes. Dis Control J. 2023;49(2):379-388. doi:10.14456/dcj.2023.32.
32. Pradeepa R, Jha V, Thyparambil Aravindakshan P, Waghdhare S, Mohan V, Chambers J, et al. 1991-LB: Triglyceride-glucose index is an effective tool for assessing glycemic control in Asian Indians with type 2 diabetes. Diabetes. 2024;73(Suppl 1):1991-LB. doi:10.2337/db24-1991-LB.
33. Bani SB, Ntim DO, Bani F, Nkansah C, Banyeh M, Dapare PPM, et al. Triglyceride-glucose index as a predictor for glycaemic control in type 2 diabetes: a retrospective study among patients attending hospital in Accra. Asian J Res Rep Endocrinol. 2025;8(1):163-174. doi:10.9734/AJRRE/2025/v8i1117.
34. Gajjar M, Mishra MK, Shah TJ, Saiyad SS, Rajput JPS. Triglyceride-glucose index and atherogenic index as alternative biomarkers for glycemic control in type 2 diabetes mellitus. Cureus. 2025;17(3):e81550. doi:10.7759/cureus.81550.
35. Ereqat S, Sharabati M, Abuhilal M, Nasereddin AF. Cost-effective markers for identifying poor glycemic control in type 2 diabetes mellitus: the role of the triglyceride-glucose index. Cureus. 2025;17(7):e88597. doi:10.7759/cureus.88597.
36. Simental-Mendía LE, Morales-Gurrola FG, Barragán-Zúñiga LJ. The triglyceride-glucose index as a surrogate measure to assess glycemic control in type 2 diabetes patients. Ir J Med Sci. 2025;194(2):515-520. doi:10.1007/s11845-025-03893-9.
37. Sánchez-García A, Rodríguez-Gutiérrez R, Mancillas-Adame L, González-Nava V, Díaz González-Colmenero A, Solis RC, et al. Diagnostic accuracy of the triglyceride and glucose index for insulin resistance: a systematic review. Int J Endocrinol. 2020;2020:4678526. doi:10.1155/2020/4678526.
38. Nabipoorashrafi SA, Seyedi SA, Rabizadeh S, Ebrahimi M, Ranjbar SA, Karimpour Reyhan S, et al. The accuracy of triglyceride-glucose (TyG) index for the screening of metabolic syndrome in adults: a systematic review and meta-analysis. Nutr Metab Cardiovasc Dis. 2022;32(12):2677-2688. doi:10.1016/j.numecd.2022.07.024.
39. Aliyu U, Toor SM, Abdalhakam I, Elrayess MA, Abou-Samra AB, Albagha OME. Evaluating indices of insulin resistance and estimating the prevalence of insulin resistance in a large biobank cohort. Front Endocrinol (Lausanne). 2025;16:1591677. doi:10.3389/fendo.2025.1591677.
40. Zhou J, Zhu L, Li Y. Association between the triglyceride glucose index and diabetic retinopathy in type 2 diabetes: a meta-analysis. Front Endocrinol (Lausanne). 2023;14:1302127. doi:10.3389/fendo.2023.1302127.
